CD8A and neoplasm: Tumor cell-derived EVs (TEVs), on the other hand, have given rise to a novel way of antitumor vaccination, by interacting with DCs systemically and facilitating endogenous tumor antigen transfer, DC maturation, and increased CD8+ T cell recruitment, infiltration, and CD4+ T cell memory [346–349].